Quick Facts: Main Uses

Clar (loratadine) is a widely available medication used to help manage symptoms related to allergies and allergic reactions. It is primarily indicated for the temporary relief of a defined set of upper respiratory allergy symptoms and certain skin reactions.

The medication may offer relief from the physical manifestations of hay fever, including sneezing, and can help address a runny nose. Additionally, it may assist in reducing the discomfort associated with itchy and watery eyes, as well as itching of the nose or throat, which often accompany environmental or seasonal allergies. It is an established option for managing these specific symptoms.

Clar is also used to manage the temporary itching and redness that result from hives, or urticaria, when this condition is part of an allergic response. The drug is considered a component in the management strategy for these common allergic presentations.

Regulatory References

1. NIH MedlinePlus guidance

Who can and cannot use Clar (Clarithromycin)?

Official regulatory documents strictly define the patient populations eligible for Clarithromycin use, primarily through absolute prohibitions.

Age and Physiological Restrictions

Clarithromycin is generally approved for use in adults and children older than 6 months. However, safety and efficacy have not been established for the treatment of general infections in infants younger than 6 months. The medicine is not recommended for use in pregnancy unless there is no appropriate alternative therapy, and nursing mothers are advised to discontinue breastfeeding during treatment. Use requires caution in patients with severe renal impairment (necessitating dose reduction) and established cardiac conditions like severe cardiac insufficiency.

Interactions with other medicines and products

This section outlines the officially documented interaction profile of Clarithromycin, strictly based on government regulatory labeling.

Official Interaction Statements

Co-administration with numerous specified medicines is formally contraindicated. These prohibitions include:

• Drugs associated with QT prolongation and serious cardiac arrhythmias, such as Astemizole, Cisapride, Pimozide, and Terfenadine.
• The statins Lovastatin and Simvastatin due to the risk of severe myopathy/rhabdomyolysis from increased plasma concentration.
• Ergotamine and Dihydroergotamine due to the risk of acute ergot toxicity.
• Colchicine, especially in the presence of renal or hepatic impairment, where toxicity risk is heightened.

Clarithromycin is documented to increase the systemic exposure of many co-administered drugs that are substrates for CYP3A or P-gp. A separate 4-hour minimum spacing rule applies to the immediate-release tablet form when co-administered with Zidovudine. A pharmacodynamic interaction with Oral Hypoglycemics/Insulin carries an additive risk of severe hypoglycemia, and the extended-release tablet's systemic exposure increases when taken with food.

Connection to the Overall Interaction Profile

Regulatory documents define this drug's interaction structure primarily through its dual role as a strong inhibitor of CYP3A and P-gp. This activity necessitates formal contraindications and mandates specific administration timing rules to manage resulting changes in drug concentrations and associated risks.

Clarithromycin's fundamental action is the targeted inhibition of bacterial growth via intervention with the ribosome, the cell's protein factory. The drug binds reversibly to the 23S ribosomal RNA within the 50S subunit, specifically blocking the Peptide Exit Tunnel. This physical obstruction halts the elongation of essential protein chains, enforcing a bacteriostatic effect that limits the replication of susceptible microbial cells. The drug’s mechanism is physiologically enhanced by the body’s conversion into its active derivative, 14-OH Clarithromycin. This metabolite shares the exact same ribosomal binding target and inhibitory function, contributing to the systemic and sustained suppression of bacterial protein synthesis. The magnitude of ribosomal inhibition is constrained by mechanisms of bacterial defense. Resistance often arises from target site methylation of the 23S rRNA or by the activation of efflux pumps that actively expel the compound, resulting in a functional failure of the inhibitory cascade.

How Clar is Used: Official Administration Guidelines

Clarithromycin (Clar) administration follows a standardized protocol to ensure proper systemic delivery of the macrolide antibacterial agent.

Official Routes and Forms

The medicine is primarily administered orally in several dosage forms, including immediate-release (IR) tablets (e.g., 250 mg and 500 mg) and extended-release (XL) tablets (e.g., 500 mg). An oral suspension is also available, intended mainly for pediatric use. Intravenous (IV) infusion is an approved route, generally reserved for hospitalized adults when oral therapy is not feasible, with a limited duration of use.

Dosing and Timing

If a dose is missed, standard protocols describe taking it as soon as remembered, unless it is nearly time for the next scheduled dose, in which case the missed dose is skipped; the dose is not doubled. IV administration requires the concentrate to be diluted and infused over 60 minutes.

Research evidence / Overview of Studies for Clar (Clarithromycin)

Evidence for Established Use in Bacterial Infections

The research base for Clarithromycin's established use in bacterial infections features Randomized Controlled Trials (RCTs) and Meta-analyses. These studies were used in research exploring how symptoms change over time and outcomes related to systemic or functional imbalance, specifically in adults and children with acute conditions.

Researchers designed these studies to measure outcomes that reflect daily functioning, primarily looking at clinical cure—or how symptoms evolved in the observed populations—and the rate at which the targeted bacteria were cleared. Findings describe patterns observed in the studies related to these measures, contributing to the broader evidence landscape as an antibacterial agent. However, research describes a significant need for continuous monitoring due to variability in bacterial resistance patterns, which may evolve over time and across different geographic regions.

Evidence for Use in Chronic Rhinosinusitis (CRS)

Clarithromycin was studied for its use in Chronic Rhinosinusitis (CRS), a condition marked by functional limitations and inflammatory states. Research was designed to explore short-term symptom changes and long-term patterns, primarily utilizing RCTs over medium to long follow-up durations (often 12 to 24 weeks) in adults.

Evidence in Specific Patient Populations

Clarithromycin was evaluated in various groups within the research landscape. Studies have monitored outcomes related to physical discomfort and functional imbalance in the pediatric population for acute infections. Research also examined specific adult groups with underlying complex conditions, such as patients with HIV and the cohort of patients with stable coronary heart disease.

Gaps and Areas of Uncertainty in the Research

The evidence highlights what is known and what is still uncertain. Evidence quality varies across studies, and findings were mixed in certain areas, such as the differences observed between specific chronic rhinosinusitis subtypes. Follow-up durations were limited for some chronic uses; therefore, long-term effects are not fully established. The evidence base must continuously account for evolving microbial resistance that can impact the patterns observed in studies over time.

Key Studies & References

1. Clarithromycin for the treatment of adult chronic rhinosinusitis: a systematic review and meta-analysis
2. Autoimmune Theories of Chronic Spontaneous Urticaria
3. Pathophysiology, Diagnosis, and Management of Chronic Spontaneous Urticaria: A Literature Review

Common questions about Clar (FAQ)

Q: What exactly is Clar used for, besides the main thing mentioned in the leaflet?

Official prescribing information indicates that Clar is used for treating various infections caused by susceptible organisms, including specific respiratory tract and skin infections. It is also approved for combination use in the eradication of H. pylori bacteria, which can cause duodenal ulcers. For other established uses, the specific indications are detailed in the full product label.

Q: Is Clar considered a high-risk medication?

Regulatory documents highlight several serious safety concerns associated with Clar, including the risk of severe cardiac issues like QT interval prolongation and the potential for liver injury (hepatotoxicity). Because of these potential risks, the official labeling contains specific warnings and precautions. The assessment of a patient's individual risk profile is performed by their healthcare provider.

Q: Does Clar interact with common over-the-counter pain relievers?

Clarithromycin is known as a strong inhibitor of the CYP3A enzyme in the body, which can increase the concentration of many other co-administered medicines. While official documents list specific contraindicated prescription drugs, this general mechanism means that other co-administered medicines, potentially including some over-the-counter pain relievers, may be subject to interaction.

Q: Is Clar safe to use for people who are older?

Official information states that older adults with normal kidney function typically do not require a change in their Clar dosage. However, caution is advised when the medicine is prescribed to older adults who have pre-existing renal impairment or established cardiac conditions. These patient populations are often placed under additional monitoring.

Q: Are there different forms of Clar (like liquid or capsule), and what's the difference?

Clar is available in several official forms, primarily immediate-release (IR) tablets, extended-release (XL) tablets, and granules for oral suspension. The XL tablets are designed to release the medicine over a longer period, which allows them to be taken once daily. The IR tablets and the suspension are generally taken every 12 hours.

Q: Is Clar similar to other drugs that treat the same condition, and how is it different?

Clar is classified as a macrolide antibiotic and is a semisynthetic compound derived from erythromycin. It shares the same core action of inhibiting bacterial protein synthesis. Its specific chemical structure gives it certain pharmacological characteristics that distinguish it from its predecessor and other similar antibiotics.

Q: Do I need to avoid any specific types of food or drink while on Clar?

The official prescribing information states that the extended-release (XL) tablet formulation must be taken with food to ensure proper absorption. The immediate-release (IR) tablet formulation, however, may be taken either with or without food. Reviewing prescription details and specific interaction warnings is recommended.

Q: What is the official definition of 'short-term use' for Clar?

The standard treatment courses for acute bacterial infections typically range from 6 to 14 days. The duration is determined by the specific infection being treated and the patient population. These timeframes define the typical short-term use of the medicine.

Q: Are there any known interactions between Clar and common supplements like vitamins or herbs?

Because Clar is a strong inhibitor of the CYP3A enzyme, it has the potential to interact with many other substances that are processed by the same enzyme system, including certain supplements or herbal products. Official guidance recommends disclosing all supplements and substances to the healthcare provider.

Q: What does 'contraindicated' mean in the context of Clar's patient information?

A contraindication is a statement in the official labeling that the medicine must not be used in a particular situation or for a specific patient population. This prohibition is established because the risk of harm in that circumstance is considered greater than any potential benefit of the medicine.

Q: Does the time of day matter when taking Clar?

The official instructions prioritize consistent spacing and adherence to the daily schedule. The immediate-release form is usually dosed every 12 hours, while the extended-release form is taken once daily. Taking the medicine at the same time each day helps to maintain a steady level in the body.

Q: If I have mild liver problems, am I still eligible to take Clar?

Clar is specifically contraindicated in patients with severe hepatic failure combined with impaired kidney function. For patients with pre-existing mild to moderate liver impairment, official labeling advises caution. Monitoring of liver function tests may be indicated during treatment.

Q: If my symptoms improve, does that mean I can stop taking Clar?

Official patient instructions state that the full course of the medicine is typically intended to be completed exactly as prescribed. This rule applies even if the patient's symptoms begin to improve or disappear. Stopping treatment early may risk the regrowth of the bacteria.

Q: How long can a person safely stay on Clar, according to official documents?

Official documents note that while established durations for acute infections are typically short, therapy for certain chronic infections may be extended over several months, as determined by clinical practice. The length of time a person stays on the medicine is determined by their specific condition.

Q: What does the term 'serious adverse reaction' mean for Clar?

According to official regulatory documents, a serious adverse reaction is an undesirable event that leads to death, is life-threatening, requires hospitalization, or results in a persistent or significant disability. The official labeling highlights several potential reactions that fall into this category.

Q: Are there any limitations on who can use Clar based on weight or body mass?

For children, the official dosing for the oral suspension is calculated based on the child's weight. For adult patients, the standard dosage is provided, and the standard regulatory labeling does not typically list specific restrictions or limitations based on adult weight or body mass index (BMI).

Q: Is it normal to have certain mild symptoms when first adjusting to Clar?

Official documents categorize side effects by how frequently they are reported. Common side effects, such as nausea, vomiting, abdominal pain, and headache, are experienced by at least 1 in 100 people. These common effects may be observed when initiating treatment.

Q: Do official documents clarify what to do if Clar doesn't seem to be working for me?

Official guidance indicates that if a patient notices no improvement in their symptoms or if their condition appears to worsen after a few days of starting the medicine, consultation with the patient's healthcare provider is indicated. This may be due to factors like bacterial resistance.

Q: What is the difference between a 'precaution' and a 'contraindication' for Clar?

A contraindication is an absolute prohibition on using the medicine in a specific situation. A precaution (or Warning/Advisory) indicates conditions where the medicine can be used, but specific monitoring or extra care is necessary to mitigate potential risks.

Q: Why is Clar sometimes associated with a specific organ function test?

Clarithromycin has been linked to potential hepatotoxicity, which is liver injury. Because of this, official documents advise monitoring the patient's liver function tests (LFTs), particularly for those with any existing liver impairment.

Q: Does Clar affect the ability to get pregnant or fertility?

Official documents advise that Clar is not recommended for use in pregnancy unless there is no appropriate alternative. While human fertility data is limited, studies conducted in animals have indicated adverse effects on reproductive parameters at high doses.

Q: Are there any specific warnings about driving or operating machinery while taking Clar?

Official documents advise that patients who experience side effects such as dizziness, vertigo (a spinning sensation), confusion, or disorientation should use caution when driving or operating machinery. These effects may impair the ability to perform such tasks safely.

Q: Can Clar affect lab test results?

The official labeling may note that Clar can interfere with the results of certain laboratory tests, such as coagulation or liver enzyme tests. Regulatory documents recommend informing laboratory personnel that the medicine is being taken before any test.

Q: Is it possible for a side effect of Clar to appear months after starting it?

Official post-marketing surveillance reports include rare, severe adverse reactions that may not manifest until sometime after treatment has begun or even after the medicine has been stopped. For example, Clostridioides difficile-associated diarrhea (CDAD) can occur up to two months after stopping.

Q: Does Clar carry a 'Black Box Warning' in the US, and what does that mean?

Official US FDA labeling indicates that Clarithromycin carries a Boxed Warning, which is a prominent warning to highlight serious or life-threatening risks. This warning draws attention to the increased long-term mortality risk observed in patients with coronary artery disease who received a two-week treatment course.

Q: Does Clar have any known effects on appetite or weight?

Official documents list appetite changes, specifically anorexia (loss of appetite), as an uncommon reported side effect of the medicine. Effects on weight are not typically listed among the commonly reported adverse reactions.

The storage and disposal of Clar (Clarithromycin) must follow specific regulatory requirements to maintain product stability.

Storage Requirements

Clarithromycin tablets must be stored at Controlled Room Temperature, typically 20 C to 25 C (68 F to 77 F). Both tablets and the granules for oral suspension must be kept in the tightly closed original container and protected from light and excessive moisture. The prepared liquid suspension must not be refrigerated and should be stored between 15 C and 30 C. This medicine must always be kept out of the sight and reach of children.

Stability and Disposal

The reconstituted oral suspension has a limited shelf-life and must be discarded after 14 days. Unused or expired clarithromycin must be safely thrown away according to official guidelines for disposal of unused medicine.